BTK Inhibitor Combinations Move to Forefront of CLL Investigations, Conversations.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 64
- By:
- Publication type:
- Article
Works matching IS 23745347 AND DT 2024 AND VI 25 AND IP 7
Results: 16
1
2
Leveraging Managed Service Organizations to Provide More Affordable, Personalized Cancer Care.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 60
- By:
- Publication type:
- Article
3
PRECISION CANCER CARE: Preserving Normal Tissue With Proton Therapy.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 56
- By:
- Publication type:
- Article
4
DENALI Study Seeks to Prove Efficacy of Azenosertib in High-Grade Serous Ovarian Cancer.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 50
- By:
- Publication type:
- Article
5
Nadofaragene Firadenovec Sets the Stage for Gene Therapies in NMIBC.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 46
- By:
- Publication type:
- Article
6
Applying the Heterogeneous Approach From NSCLC TO SCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 41
- By:
- Publication type:
- Article
7
The Benefits Outweigh the Risks: Unpacking the Recent ODAC Decisions in Myeloma.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 33
- By:
- Publication type:
- Article
8
Advances in MRD Testing Help Guide Optimal Colorectal Cancer Therapy.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 24
- By:
- Publication type:
- Article
9
MRD-Negative CR Separates Ponatinib From the Rest in Newly Diagnosed, Ph+ ALL.
- Published in:
- 2024
- By:
- Publication type:
- Interview
10
A First in CLL/SLL: Liso-Cel Makes its Mark as Only Approved CAR T-Cell Therapy.
- Published in:
- 2024
- By:
- Publication type:
- Interview
11
Zanubrutinib Plus Obinutuzumab Gets Go-Ahead for Relapsed or Refractory Follicular Lymphoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 8
- Publication type:
- Article
12
Nivolumab Tacks on Indication With Chemo for Frontline Unresectable or Metastatic Urothelial Carcinoma.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 8
- Publication type:
- Article
13
Inotuzumab Ozogamicin Gains Approval for Pediatric CD22+ B-Cell Precursor ALL.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 8
- Publication type:
- Article
14
Frontline Amivantamab Plus Chemotherapy Gets Greenlight for EGFR Exon 20 Insertion+ NSCLC.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 8
- Publication type:
- Article
15
IMPROVED SURVIVAL IN RANDOMIZED TRIALS: A Meaningful Outcome but Increasingly Difficult to Demonstrate.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 6
- By:
- Publication type:
- Article
16
Innovations Break the Mold as New Treatment Options Move Forward.
- Published in:
- OncologyLive, 2024, v. 25, n. 7, p. 4
- By:
- Publication type:
- Article